The Role of Antiplatelet agents in ischemic events
Abstract
Antiplatelet treatment could be a key in pharmacological treatment for avoidance of coronary heart disease (CHD) and stroke. Depending on sign, term of antiplatelet monotherapy or double treatment is shifted. Antiplatelet treatment is shown to avoid a repeat of cardiovascular occasion, in any case, expanded term of dual antiplatelet treatment (DAPT) related with expanded hazard of bleeding. Unstable angina happens due to partially or totally block of the blood coronary blood vessel driving to coronary ischaemia. Intense coronary infection happens due to drawn out coronary ischaemia which causes coronary diseases.
Keywords: dual antiplatelet treatment (DAPT), coronary heart disease (CHD) and stroke.
Keywords:
dual antiplatelet treatment (DAPT), coronary heart disease (CHD), strokeDOI
https://doi.org/10.22270/jddt.v11i4-S.4926References
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [Internet]. Eur. Heart J. 2016; 37(38):2893-962. Available from: https://academic.oup.com/eurheartj/article/37/38/2893/2334964
CJ M, T V, R L, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England) [Internet] 2012; 380(9859):2197-223. Available from: https://pubmed.ncbi.nlm.nih.gov/23245608/
M D, A O, W C, M T. Balancing between bleeding and thromboembolism after percutaneous coronary intervention in patients with atrial fibrillation. Could triple anticoagulant therapy be a solution? Postep w Kardiol interwencyjnej = Adv Interv Cardiol [Internet] 2013; 9(3):234-40. Available from: https://pubmed.ncbi.nlm.nih.gov/24570724/ https://doi.org/10.5114/pwki.2013.37501
Miner J, Hoffhines A. The Discovery of Aspirin's Antithrombotic Effects. Texas Hear Inst J [Internet] 2007; 34(2):179. Available from: /pmc/articles/PMC1894700/
Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest [Internet] 2004; 126(3):234S-264S. Available from: http://journal.chestnet.org/article/S0012369215314938/fulltext https://doi.org/10.1378/chest.126.3_suppl.234S
R DV, C C, D M. Clinical Relevance of Anticoagulation and Dual Antiplatelet Therapy to the Outcomes of Patients With Atrial Fibrillation and Recent Percutaneous Coronary Intervention With Stent. J Clin Med Res [Internet] 2016; 8(2):153-61. Available from: https://pubmed.ncbi.nlm.nih.gov/26767085/ https://doi.org/10.14740/jocmr2443w
F C-L, MP R, SC K, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med [Internet] 2001; 345(25):1809-17. Available from: https://pubmed.ncbi.nlm.nih.gov/11752357/ https://doi.org/10.1056/NEJMoa003199
C B, L B, R C, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (London, England) [Internet] 2009; 373(9678):1849-60. Available from: https://pubmed.ncbi.nlm.nih.gov/19482214/ https://doi.org/10.1016/S0140-6736(09)60503-1
S Y, S R, S O, S A. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation [Internet] 200; 104(22):2746-53. Available from: https://pubmed.ncbi.nlm.nih.gov/11723030/ https://doi.org/10.1161/hc4601.099487
Altman EI, Marco G, Varetto F. Corporate distress diagnosis: Comparisons using linear discriminant analysis and neural networks (the Italian experience). J Bank Financ 1994; 18(3):505-29. https://doi.org/10.1016/0378-4266(94)90007-8
ES J, SF L, CE W, MH S, BL A, LW D. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med [Internet] 199; 159(11):1248-53. Available from: https://pubmed.ncbi.nlm.nih.gov/10371234/ https://doi.org/10.1001/archinte.159.11.1248
PM R, A A, Z C, HC D, B N, Z M. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet (London, England) [Internet] 201; 388(10042):365-75. Available from: https://pubmed.ncbi.nlm.nih.gov/27209146/ https://doi.org/10.1016/S0140-6736(16)30468-8
PT O, FG K, DD A, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation [Internet] 2013;127(4). Available from: https://pubmed.ncbi.nlm.nih.gov/23247304/
SE F, C L, CD N, E C, GT C, BS G. Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis. Eur J Cardiothorac Surg [Internet] 1993; 7(4):169-80. Available from: https://pubmed.ncbi.nlm.nih.gov/8481254/ https://doi.org/10.1016/1010-7940(93)90155-5
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ [Internet] 2002; 324(7329):71-86. Available from: https://pubmed.ncbi.nlm.nih.gov/11786451/ https://doi.org/10.1136/bmj.324.7329.71
LA H, RA K. Mechanism of action of dipyridamole. Thromb Res Suppl [Internet] 1983;4(SUPPL. 1):39-46. Available from: https://pubmed.ncbi.nlm.nih.gov/6356465/
Maffrand JP. The story of clopidogrel and its predecessor, ticlopidine: Could these major antiplatelet and antithrombotic drugs be discovered and developed today? Comptes Rendus Chim 2012; 15(8):737-43. https://doi.org/10.1016/j.crci.2012.05.006
J J, SP K. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A [Internet] 1998; 95(14):8070-4. Available from: https://pubmed.ncbi.nlm.nih.gov/9653141/ https://doi.org/10.1073/pnas.95.14.8070
G H, HM J, D V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature [Internet] 2001; 409(6817):202-7. Available from: https://pubmed.ncbi.nlm.nih.gov/11196645/ https://doi.org/10.1038/35051599
P S, JM H. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost [Internet] 2005; 31(2):174-83. Available from: https://pubmed.ncbi.nlm.nih.gov/15852221/ https://doi.org/10.1055/s-2005-869523
M G, JA B, JD E, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet (London, England) [Internet] 1989; 1(8649):1215-20. Available from: https://pubmed.ncbi.nlm.nih.gov/2566778/ https://doi.org/10.1016/S0140-6736(89)92327-1
Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 2003; 3(2):113-21. https://doi.org/10.1055/s-2003-40669
EL F, TY W, S L, et al. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. Am Heart J [Internet] 2013; 166(5):864-70. Available from: https://pubmed.ncbi.nlm.nih.gov/24176442/ https://doi.org/10.1016/j.ahj.2013.08.005
DA L, HO L, D V, et al. Reduced fetal growth rate and increased risk of death from ischaemic heart disease: cohort study of 15 000 Swedish men and women born 1915-29. BMJ [Internet] 1998; 317(7153):241-5. Available from: https://pubmed.ncbi.nlm.nih.gov/9677213/ https://doi.org/10.1136/bmj.317.7153.241
Bennett CL, Connors JM, Carwile JM, et al. Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel. http://dx.doi.org/101056/NEJM200006153422402 [Internet] 2009; 342(24):1773-7. Available from: https://www.nejm.org/doi/full/10.1056/NEJM200006153422402
K G, K N, S S, et al. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol [Internet] 2014; 114(1):70-8. Available from: https://pubmed.ncbi.nlm.nih.gov/24925801/
Steinhubl SR, Berger PB, III JTM, et al. Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Randomized Controlled Trial. JAMA [Internet] 2002; 288(19):2411-20. Available from: https://jamanetwork.com/journals/jama/fullarticle/195532 https://doi.org/10.1001/jama.288.19.2411
S Y, S R, S O, S A. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation [Internet] 2001; 104(22):2746-53. Available from: https://pubmed.ncbi.nlm.nih.gov/11723030/ https://doi.org/10.1161/hc4601.099487
CN H, ED P, SA P, et al. Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. J Am Coll Cardiol [Internet] 2015; 66(6):616-27. Available from: https://pubmed.ncbi.nlm.nih.gov/26248987/
ME B, HJ R, P U, AH G. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation [Internet] 2000; 102(6):624-9. Available from: https://pubmed.ncbi.nlm.nih.gov/10931801/ https://doi.org/10.1161/01.CIR.102.6.624
DL B, KA F, W H, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med [Internet] 2006; 354(16):1706-17. Available from: https://pubmed.ncbi.nlm.nih.gov/16531616/
ME B, V L, J B, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation [Internet] 1998; 98(16):1597-603. Available from: https://pubmed.ncbi.nlm.nih.gov/9778323/ https://doi.org/10.1161/01.CIR.98.16.1597
SV D, SM D, IK S, et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Card Surg [Internet] 2013; 28(2):109-16. Available from: https://pubmed.ncbi.nlm.nih.gov/23488578/ https://doi.org/10.1111/jocs.12074
PK S, LT G, JH L, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol [Internet] 2012; 60(5):388-96. Available from: https://pubmed.ncbi.nlm.nih.gov/22633653/ https://doi.org/10.1016/j.jacc.2012.03.030
RL S, HC D, S Y, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med [Internet] 2008; 359(12):1238-51. Available from: https://pubmed.ncbi.nlm.nih.gov/18753638/
Kawai H, Watanabe E, Yamamoto M, et al. Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting. J Cardiol 2015; 65(3):197-202. https://doi.org/10.1016/j.jjcc.2014.08.013
Roe MT, Armstrong PW, Fox KAA, et al. Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. http://dx.doi.org/101056/NEJMoa1205512 [Internet] 2012; 367(14):1297-309. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1205512
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. http://dx.doi.org/101056/NEJMoa0706482 [Internet] 2009; 357(20):2001-15. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa0706482 https://doi.org/10.1056/NEJMoa0706482
Giezen JJJ van, Humphries RG. Preclinical and Clinical Studies with Selective Reversible Direct P2Y12 Antagonists. Semin Thromb Hemost [Internet] 2005; 31(02):195-204. Available from: http://www.thieme-connect.com/products/ejournals/html/10.1055/s-2005-869525 https://doi.org/10.1055/s-2005-869525
Husted S, Giezen JJJ Van. Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist. Cardiovasc Ther [Internet] 2009; 27(4):259-74. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1755-5922.2009.00096.x https://doi.org/10.1111/j.1755-5922.2009.00096.x
PA G, KP B, K B, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation [Internet] 2009; 120(25):2577-85. Available from: https://pubmed.ncbi.nlm.nih.gov/19923168/ https://doi.org/10.1161/CIRCULATIONAHA.109.912550
L B, US T, R M, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol [Internet] 2010; 56(12):919-33. Available from: https://pubmed.ncbi.nlm.nih.gov/20828644/ https://doi.org/10.1016/j.jacc.2010.04.047
L W, RC B, A B, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med [Internet] 2009; 361(11):1045-57. Available from: https://pubmed.ncbi.nlm.nih.gov/19717846/
L M, A S, J F, et al. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience. Med Klin (Munich) [Internet] 2008; 103(9):628-32. Available from: https://europepmc.org/article/med/18813885 https://doi.org/10.1007/s00063-008-1101-4
Held C, Senblad N, Bassand JP, et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Coll Cardiol 2011; 57(6):672-84. https://doi.org/10.1016/j.jacc.2010.10.029
N S, G N, J M, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med [Internet] 2008; 264(5):472-80. Available from: https://pubmed.ncbi.nlm.nih.gov/18624903/ https://doi.org/10.1111/j.1365-2796.2008.01989.x
G C, P A, P J. Anti-thromboembolic strategies in atrial fibrillation. Cardiol J [Internet] 2016; 23(2):211-23. Available from: https://pubmed.ncbi.nlm.nih.gov/26779967/ https://doi.org/10.5603/CJ.a2016.0004
Published
Abstract Display: 397 
PDF Downloads: 602 PDF Downloads: 45 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.